22Q11.2 Deletion Syndrome
·MeSH: DiGeorge Syndrome
Prevalence
30.0 / 100K
3 drugs in development·3 companies·1 clinical trial
Drug Pipeline by Phase
Phase 2(2)
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| zygel | Zynerba Pharmaceuticals, Inc. (ZYNE) |
Compare drugs
Frequently asked questions
How many drugs are in development for 22Q11.2 Deletion Syndrome?
BioSniper tracks 3 drugs in development for 22Q11.2 Deletion Syndrome across 3 companies.
How many clinical trials target 22Q11.2 Deletion Syndrome?
There are 1 clinical trial targeting 22Q11.2 Deletion Syndrome tracked by BioSniper.
What is the prevalence of 22Q11.2 Deletion Syndrome?
The estimated prevalence of 22Q11.2 Deletion Syndrome is approximately 30.0 per 100,000 population.
Deep-dive into 22Q11.2 Deletion Syndrome
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis